Knowledge Center

Clinical Trials Knowledge Center – Articles, FAQ & Glossary

 
Clinical Trials Frequently Asked Questions

Clinical Trial Glossary
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Glossary results: T

An adverse effect produced by a drug that is detrimental to the participant's health. The level of toxicity associated with a drug will vary depending on the condition that the drug is used to treat.

IND stands for investigational new drug application, which is part of the process to get approval from the FDA for marketing a new prescription drug in the U.S. It makes promising new drugs available to desperately ill participants as early in the drug development process as possible. Treatment INDs are made available to participants before general marketing begins, typically during Phase III studies. To be considered for a treatment IND, a participant cannot be eligible to be in the definitive clinical trial.

Refers to trials that test new treatments, new combinations of drugs or new approaches to surgery or radiation therapy.


ClinicalTrials.com provides links to other Internet sites for the user's convenience. ClinicalTrials.com is not responsible for the availability or content of these external sites, nor does it endorse, warrant or guarantee the products, services or information described or offered at these sites.

Information included in the Glossary is from Clinicaltrials.gov, which uses content from AIDSinfo, CenterWatch, Inc., ECRI, Eli Lilly and Company, MediStudy.com, Inc. and National Cancer Institute.